<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02875080</url>
  </required_header>
  <id_info>
    <org_study_id>331-102-00019</org_study_id>
    <secondary_id>JapicCTI-163351</secondary_id>
    <nct_id>NCT02875080</nct_id>
  </id_info>
  <brief_title>Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects</brief_title>
  <official_title>A Single-center, Open-label, Randomized, Three-way, Crossover Trial to Evaluate the Bioavailability of Brexpiprazole (OPC-34712) Orally Disintegrating Tablets Relative to Brexpiprazole (OPC-34712) Conventional Tablets in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ratios of the geometric means of the ODT formulation to those of the reference&#xD;
      formulation (conventional tablet) for the bioavailability variables (Cmax, AUCt, and AUC∞ of&#xD;
      brexpiprazole (OPC-34712)).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 27, 2016</start_date>
  <completion_date type="Actual">November 27, 2016</completion_date>
  <primary_completion_date type="Actual">November 27, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of OPC-34712</measure>
    <time_frame>Predose, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, 120，144, 168, 216, 264, and 312 hours postdose</time_frame>
    <description>To evaluate Cmax of OPC-34712 4-mg ODT formulation relative to 4-mg conventional tablet formulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC∞) of OPC-34712</measure>
    <time_frame>Predose, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, 120，144, 168, 216, 264, and 312 hours postdose</time_frame>
    <description>To evaluate AUC∞ of OPC-34712 4-mg ODT formulation relative to 4-mg conventional tablet formulation</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Adult Male</condition>
  <arm_group>
    <arm_group_label>OPC-34712 disintegrating tablet with water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-34712 (4 mg) orally disintegrating tablet is administered with water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-34712 disintegrating tablet without water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-34712 (4 mg) orally disintegrating tablet is administered without water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPC-34712 conventional tablet with water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OPC-34712 (4 mg) conventional tablet is administered with water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-34712</intervention_name>
    <arm_group_label>OPC-34712 conventional tablet with water</arm_group_label>
    <arm_group_label>OPC-34712 disintegrating tablet with water</arm_group_label>
    <arm_group_label>OPC-34712 disintegrating tablet without water</arm_group_label>
    <other_name>Brexpiprazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Capable of providing written informed consent prior to initiation of any trial-related&#xD;
             procedures, and able, in the opinion of the investigator, to comply with all&#xD;
             requirements of the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant abnormality at the time of screening (eg, significant deviation&#xD;
             from reference ranges) or in medical history that, in the opinion of investigator or&#xD;
             sponsor may place the subject at risk or interfere with outcome variables, including&#xD;
             drug absorption, distribution, metabolism, and excretion&#xD;
&#xD;
          -  History of serious mental disorder&#xD;
&#xD;
          -  History of drug or alcohol abuse within 2 years prior to screening&#xD;
&#xD;
          -  History of any significant drug allergy&#xD;
&#xD;
          -  Use of an investigational drug within 120 days prior to the first dosing of trial drug&#xD;
&#xD;
          -  Use of tobacco products or daily exposure to secondhand smoke within 2 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Consumption of grapefruit, grapefruit products, Seville oranges, Seville orange&#xD;
             products, starfruit, or starfruit products within 72 hours prior to dosing&#xD;
&#xD;
          -  Use of prescription, over-the-counter, or herbal medication, vitamin supplements, or&#xD;
             St. John's Wort within 14 days prior to the first dosing of trial drug, or of&#xD;
             antibiotics within 30 days prior to the first dosing of trial drug&#xD;
&#xD;
          -  History of major surgery of the digestive tract (excluding appendectomy)&#xD;
&#xD;
          -  Any subject who, in the opinion of the investigator, should not participate in the&#xD;
             trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Ono, Mr</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kyusyu Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>August 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <results_first_submitted>February 3, 2021</results_first_submitted>
  <results_first_submitted_qc>February 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2021</results_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brexpiprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 33 subjects were screened for participation in this trial. Of the 33 subjects, 18 subjects were enrolled and randomized to one of 3 sequences, each consisting of 6 subjects. Of the 6 subjects in the Sequence 1 group, 6 subjects received a single dose of OPC-34712 orally disintegrating tablet (ODT) without water, 5 subjects received a single dose of OPC-34712 conventional tablet, and 4 subjects received a single dose of OPC-34712 ODT with water.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1</title>
          <description>Subjects randomized to Sequence 1 received an ODT without water on Day 1, a conventional tablet on Day 21, and an ODT with water on Day 41.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2</title>
          <description>Subjects randomized to Sequence 2 received an ODT with water on Day 1, an ODT without water on Day 21, and a conventional tablet on Day 41.</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3</title>
          <description>Subjects randomized to Sequence 3 received a conventional tablet on Day 1, an ODT with water on Day 21, and an ODT without water on Day 41.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Positive urine test for cotinine on Day 20 or Day 40</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence 1</title>
          <description>Subjects randomized to Sequence 1 received an ODT without water on Day 1, a conventional tablet on Day 21, and an ODT with water on Day 41.</description>
        </group>
        <group group_id="B2">
          <title>Sequence 2</title>
          <description>Subjects randomized to Sequence 2 received an ODT with water on Day 1, an ODT without water on Day 21, and a conventional tablet on Day 41.</description>
        </group>
        <group group_id="B3">
          <title>Sequence 3</title>
          <description>Subjects randomized to Sequence 3 received a conventional tablet on Day 1, an ODT with water on Day 21, and an ODT without water on Day 41.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.8" spread="5.5"/>
                    <measurement group_id="B2" value="29.7" spread="7.4"/>
                    <measurement group_id="B3" value="28.7" spread="8.0"/>
                    <measurement group_id="B4" value="30.4" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) of OPC-34712</title>
        <description>To evaluate Cmax of OPC-34712 4-mg ODT formulation relative to 4-mg conventional tablet formulation</description>
        <time_frame>Predose, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, 120，144, 168, 216, 264, and 312 hours postdose</time_frame>
        <population>Pharmacokinetic analysis set consisted of subjects with all evaluable PK parameters from enrolled subjects who had evaluable plasma concentrations. No data imputation was done for missing data, ie, missing data remained missing for the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>OPC-34712 Disintegrating Tablet With Water</title>
            <description>OPC-34712 (4 mg) orally disintegrating tablet is administered with water.</description>
          </group>
          <group group_id="O2">
            <title>OPC-34712 Disintegrating Tablet Without Water</title>
            <description>OPC-34712 (4 mg) orally disintegrating tablet is administered without water.</description>
          </group>
          <group group_id="O3">
            <title>OPC-34712 Conventional Tablet With Water</title>
            <description>OPC-34712 (4 mg) conventional tablet is administered with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of OPC-34712</title>
          <description>To evaluate Cmax of OPC-34712 4-mg ODT formulation relative to 4-mg conventional tablet formulation</description>
          <population>Pharmacokinetic analysis set consisted of subjects with all evaluable PK parameters from enrolled subjects who had evaluable plasma concentrations. No data imputation was done for missing data, ie, missing data remained missing for the analyses.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="10.0"/>
                    <measurement group_id="O2" value="44.9" spread="13.8"/>
                    <measurement group_id="O3" value="46.1" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC∞) of OPC-34712</title>
        <description>To evaluate AUC∞ of OPC-34712 4-mg ODT formulation relative to 4-mg conventional tablet formulation</description>
        <time_frame>Predose, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, 120，144, 168, 216, 264, and 312 hours postdose</time_frame>
        <population>Pharmacokinetic analysis set consisted of subjects with all evaluable PK parameters from enrolled subjects who had evaluable plasma concentrations. No data imputation was done for missing data, ie, missing data remained missing for the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>OPC-34712 Disintegrating Tablet With Water</title>
            <description>OPC-34712 (4 mg) orally disintegrating tablet is administered with water.</description>
          </group>
          <group group_id="O2">
            <title>OPC-34712 Disintegrating Tablet Without Water</title>
            <description>OPC-34712 (4 mg) orally disintegrating tablet is administered without water.</description>
          </group>
          <group group_id="O3">
            <title>OPC-34712 Conventional Tablet With Water</title>
            <description>OPC-34712 (4 mg) conventional tablet is administered with water.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC∞) of OPC-34712</title>
          <description>To evaluate AUC∞ of OPC-34712 4-mg ODT formulation relative to 4-mg conventional tablet formulation</description>
          <population>Pharmacokinetic analysis set consisted of subjects with all evaluable PK parameters from enrolled subjects who had evaluable plasma concentrations. No data imputation was done for missing data, ie, missing data remained missing for the analyses.</population>
          <units>ng·h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2920" spread="1630"/>
                    <measurement group_id="O2" value="2830" spread="1270"/>
                    <measurement group_id="O3" value="2770" spread="1460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of IMP administration throughout follow-up period (up to 22 days after the last dose of IMP)</time_frame>
      <desc>A treatment-emergent adverse event (AE) was defined as an AE that started after start of IMP, or an AE that continued from baseline and became serious, IMP-related, or resulted in death, discontinuation, interruption or reduction of trial medication. The safety analysis dataset included all subjects that were administered at least one dose of IMP.</desc>
      <group_list>
        <group group_id="E1">
          <title>OPC-34712 Disintegrating Tablet With Water</title>
          <description>OPC-34712 (4 mg) orally disintegrating tablet is administered with water.</description>
        </group>
        <group group_id="E2">
          <title>OPC-34712 Disintegrating Tablet Without Water</title>
          <description>OPC-34712 (4 mg) orally disintegrating tablet is administered without water.</description>
        </group>
        <group group_id="E3">
          <title>OPC-34712 Conventional Tablet With Water</title>
          <description>OPC-34712 (4 mg) conventional tablet is administered with water.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Ver. 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Otsuka Pharmaceutical Co., LTD.</organization>
      <phone>+81-3-6361-7366</phone>
      <email>CL_OPCJ_RDA_Team@otsuka.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

